UCT-MSC Stem Cells for Spinal & Interventional Pain Practices: A Supplier Documentation Guide
Licensed spinal surgery centers, interventional pain physicians, and neurosurgeons sourcing UCT-MSC biologics face a documentation challenge that other practice verticals do not. The quality specifications that matter most are more stringent, and the questions to ask a supplier are more specific.
This guide covers what licensed spinal and interventional pain practitioners need to evaluate when sourcing UCT-MSC biologics — focused entirely on documentation, quality specifications, and supplier standards. It does not constitute clinical guidance, protocol direction, or legal advice.
Why Documentation Standards Are Higher for This Vertical
UCT-MSC sourcing for spinal and interventional pain applications requires the most stringent documentation standard of any biologic use category. The documentation parameters that matter most — mycoplasma threshold, sterility method, viral panel completeness, and viability at point of use — are not uniformly met by the broader stem cell supplier market.
What follows are the specific parameters to verify before any purchase.
The Documentation Checklist
Post-Thaw Viability — Require ≥ 90%, Not Just ≥ 70%
The industry standard minimum is 70%. For applications where live cell delivery is the intent, viability at point of use matters significantly. Require lot-specific viability documentation on the final shipped product. Stem Nova current lot: 97% post-thaw viability, instrument-verified.
Mycoplasma — Require ≤ 0.02 Threshold, Lot-Specific
Mycoplasma specification and result must appear on the lot-specific CoA for the vials being shipped. The ≤ 0.02 threshold is the appropriate specification for this application category. A general "mycoplasma: negative" without a quantitative threshold and lot-specific result is insufficient. Stem Nova: Mycoplasma Negative, confirmed ≤ 0.02, lot-documented.
Full Nine-Marker Viral Screening Panel
HCV, HIV, HBV, HTLV, CMV, EBV, HHV, HPV, and B19 — all nine markers must be tested and documented as negative on the lot-specific CoA. Suppliers who provide a partial viral panel are not meeting the appropriate standard for this category. Stem Nova: full nine-marker panel, all Negative, lot-documented.
Sterility — 21 CFR 610.12, Lot-Specific
Sterility testing must be performed per 21 CFR 610.12 on each individual lot. Request the test date and lot-specific result for the exact vials in your order. Stem Nova: Sterility Negative per 21 CFR 610.12, lot-documented.
Flow Cytometry — CD90 and CD166 ≥ 80%
ISCT-defined MSC identity markers confirmed by flow cytometry on the specific lot being shipped. Confirms the cells are mesenchymal stem cells meeting the International Society for Cell and Gene Therapy phenotypic criteria. Stem Nova: CD90 100%, CD166 100%, lot-documented.
Endotoxin — USP <85>, Lot-Specific
Endotoxin must be tested per USP <85> with a specification of ≤ 10 EU/mL and a lot-specific result on the CoA. Stem Nova: 0.935 EU/mL, lot-documented.
AATB-Accredited, FDA-Registered Tissue Establishment — cGTP Compliant
Sourcing from an AATB-accredited, FDA-registered facility operating under cGTP standards (21 CFR Part 1271) is the strongest available manufacturing quality signal for allogeneic biologic products. Confirm the facility's FDA registration and AATB accreditation status before purchasing. These are facility credentials — not product approval.
Full Lot Documentation — What Stem Nova Ships on Every Order
| Parameter | Specification | SNN Lot Result |
|---|---|---|
| Post-Thaw Viability | ≥ 70% (industry standard) | 97% |
| Cell Count | ≥ 2.0 × 10⁷ cells/vial | 2.4 × 10⁷ cells/vial |
| CD90 Expression | ≥ 80% (ISCT standard) | 100% |
| CD166 Expression | ≥ 80% (ISCT standard) | 100% |
| Endotoxin | ≤ 10 EU/mL (USP <85>) | 0.935 EU/mL |
| Sterility | Negative (21 CFR 610.12) | Negative |
| Mycoplasma | Negative · ≤ 0.02 threshold | Confirmed ≤ 0.02 |
| Full Viral Panel (9 markers) | Negative | All Negative |
Questions to Ask Any UCT-MSC Supplier
- "Can I see the CoA for the specific lot I'm receiving?" — Not a sample, not a product-line template.
- "What is your mycoplasma threshold and is it documented per lot?" — Require ≤ 0.02 with a lot-specific result.
- "What nine viral markers are included in your screening panel?" — Require all nine listed above.
- "What is the post-thaw viability of the lot I'm receiving?" — Require a lot-specific instrument-verified result.
- "Is your facility AATB-accredited and FDA-registered?" — Require confirmation of both.
- "Does your facility operate under cGTP standards per 21 CFR Part 1271?" — Require confirmation.
Request Documentation Before You Source
Full lot-specific CoA, viral panel, mycoplasma-verified lots, and cGTP-compliant manufacturing documentation — available to licensed practitioners upon credential verification. Most practices approved within 24 hours.
Enroll Your Practice Today → Contact Our TeamFrequently Asked Questions
Why does the mycoplasma threshold matter for this application category?
Mycoplasma contamination in a cell product is a serious safety concern for any high-sensitivity application. A stringent specification (≤ 0.02) with lot-specific documentation gives practitioners confidence in the quality of each individual lot — not just the product line in general.
What is the difference between a lot-specific CoA and a product-line CoA?
A lot-specific CoA documents test results for the specific production batch — the actual vials you receive. A product-line CoA is a generic document showing representative specifications that does not reflect the specific lot in your order. Lot-specific CoAs are the only acceptable standard for this documentation level.
Are these products FDA-approved?
No. UCT-MSC stem cell biologics are not FDA-approved drugs or therapeutic agents. The only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood for limited hematopoietic uses. AATB accreditation, FDA-registered facility status, and cGTP-compliant manufacturing are facility credentials — they do not constitute product approval for any indication.
Related Resources
- UCT-MSC Stem Cells: What Regenerative Clinics Need to Know
- Are Exosomes FDA Approved? What Practitioners Need to Understand
- UCT-MSC Stem Cells for Spinal & Interventional Pain Practices
- UCT-MSC Stem Cells for Orthopedic & Pain Practices
- Quality & Testing Standards: CoAs, Viral Panel, and cGTP-Compliant Manufacturing